P

Porton Pharma Solutions Ltd
SZSE:300363

Watchlist Manager
Porton Pharma Solutions Ltd
SZSE:300363
Watchlist
Price: 23.67 CNY 0.72% Market Closed
Market Cap: 12.9B CNY

Porton Pharma Solutions Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Porton Pharma Solutions Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
P
Porton Pharma Solutions Ltd
SZSE:300363
Revenue
ÂĄ3.4B
CAGR 3-Years
-18%
CAGR 5-Years
12%
CAGR 10-Years
12%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Revenue
ÂĄ13.2B
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Revenue
ÂĄ9.8B
CAGR 3-Years
5%
CAGR 5-Years
9%
CAGR 10-Years
19%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Revenue
ÂĄ31B
CAGR 3-Years
13%
CAGR 5-Years
4%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Revenue
ÂĄ40.8B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Revenue
ÂĄ5.8B
CAGR 3-Years
94%
CAGR 5-Years
37%
CAGR 10-Years
N/A
No Stocks Found

Porton Pharma Solutions Ltd
Glance View

Market Cap
12.9B CNY
Industry
Pharmaceuticals

Porton Pharma Solutions Ltd., rooted in the vibrant landscape of China's pharmaceutical sector, has strategically navigated its way to becoming a pivotal player in the global Contract Development and Manufacturing Organization (CDMO) industry. Founded in 2005, the company harnesses the intricate synergy between chemistry and biology to drive its core operations. Porton specializes in providing a comprehensive suite of services ranging from early drug development to commercial-scale manufacturing. The company's business model thrives on forming collaborative partnerships with global pharmaceutical and biotechnology firms, offering customized solutions tailored to specific drug production needs. By acting as an extension of its clients' research and development teams, Porton effectively reduces the time and investment required for its clients to bring new drugs to market, catalyzing its own revenue through long-standing service agreements. The essence of Porton’s value proposition lies in its robust technological capabilities and commitment to compliance with international quality standards, which ensures client trust and repeat business. Porton's facilities are outfitted with cutting-edge technologies that support complex chemical synthesis and advanced bioprocessing, allowing them to expertly handle high-potency and complex molecules. Additionally, the company leverages its strategic geographic advantage in China to offer competitive pricing while maintaining quality excellence, a crucial factor in contracting agreements. Through continuous investments in research and development, and a commitment to operational efficiency, Porton Pharma Solutions Ltd. not only accelerates its clients' drug development timelines but also enhances its own profitability, positioning itself as a leader in the evolving CDMO landscape.

Intrinsic Value
18.39 CNY
Overvaluation 22%
Intrinsic Value
Price
P

See Also

What is Porton Pharma Solutions Ltd's Revenue?
Revenue
3.4B CNY

Based on the financial report for Sep 30, 2025, Porton Pharma Solutions Ltd's Revenue amounts to 3.4B CNY.

What is Porton Pharma Solutions Ltd's Revenue growth rate?
Revenue CAGR 10Y
12%

Over the last year, the Revenue growth was 25%. The average annual Revenue growth rates for Porton Pharma Solutions Ltd have been -18% over the past three years , 12% over the past five years , and 12% over the past ten years .

Back to Top